Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen announces U.S. FDA granted Fast Track designation to BIIB080
- Organon acquires rights for Tofidence from Biogen
- Biogen’s Favorable Outlook: Navigating Regulatory Challenges and Safety Advantages Justify Buy Rating
- Biogen announces plans for new global HQ, innovation hub at Kendall Common
- Biogen call volume above normal and directionally bullish